Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients
Status:
Completed
Trial end date:
2018-12-14
Target enrollment:
Participant gender:
Summary
This study will assess the effect of a 24-week withdrawal followed by a 28-week
reintroduction of belimumab 10 mg/kg plus standard of care medications in subjects with
stable low systemic lupus erythematosus (SLE) disease activity. Rebound phenomenon will be
assessed for subjects who have permanently withdrawn from further belimumab treatment.